Test drug DR-01 for specific blood cancer types
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This early-phase study tests DR-01 to treat large granular lymphocytic leukemia (LGLL) or certain aggressive T-cell or cytotoxic lymphomas. It aims to see whether the drug is safe and can shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old and be able to sign consent and follow study visits.
- You must have adequate heart, blood clotting, and organ function on screening tests.
- If you can become pregnant, you must use highly effective birth control starting now and continuing through at least 12 months after the last dose.
- If you are able to father a pregnancy, you must agree to use effective birth control during the study.
- You must have stopped at least one prior cancer treatment (for the LGLL group).
- You must meet the specific diagnosis and measurable disease rules for the lymphoma group (including scans and/or biopsy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests an experimental medicine (RNK05047) in people with advanced solid tumors or diffuse large B‑cell lymphoma whose standard treatments haven’t worked or can’t be tolerated. It may help shrink tumors and improve control of the disease, but early-phase trials also focus on safety and dosing.
This Phase 1/2 trial tests CRC01, a lab-made immune cell therapy, for adults whose lymphoma or B-cell leukemia has come back or did not respond to treatment. If you qualify, the study aims to see how safe CRC01 is and whether it can shrink tumors and improve outcomes.
This trial tests whether the experimental drug TC011 can help adults with a type of B-cell lymphoma that has come back or stopped responding after at least two rounds of chemotherapy. The study checks for safety and whether the treatment can shrink tumors.
This trial tests an experimental drug, SAR448501/DR-0201, for people with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments. The goal is to see if the drug is safe and can shrink tumors.
This Phase 1 study tests BRL-201 (an anti-CD19 treatment) for safety and early signs of effectiveness in adults with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. It may help people whose lymphoma has returned or not responded to prior treatments.
This trial tests a new drug called DT-7012 for people with a type of skin lymphoma (mycosis fungoides or Sezary syndrome) that has come back or not responded to at least two prior treatments. The goal is to find a safe dose and see if it shrinks the lymphoma.
Hear when a new Hepatosplenic T-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.